Format

Send to

Choose Destination
Arch Neurol. 2008 Dec;65(12):1655-8. doi: 10.1001/archneur.65.12.1655.

Natalizumab use in pediatric multiple sclerosis.

Author information

1
Department of Pediatrics and Pediatric Neurology, Faculty of Medicine, Georg August University, Robert-Koch-Strasse 40, D-37075 Göttingen, Germany.

Abstract

BACKGROUND:

Natalizumab, a humanized monoclonal antibody raised against alpha4 integrins, is approved for treatment of active relapsing-remitting multiple sclerosis (RRMS) in adult patients.

OBJECTIVE:

To determine the safety, effectiveness, and tolerability of natalizumab use in pediatric patients with MS.

DESIGN:

Case report.

SETTING:

Center for MS in childhood and adolescents, Göttingen, Germany.

PATIENTS:

Three pediatric patients with RRMS having a poor response to other immunomodulatory therapies or having intolerable adverse effects.

INTERVENTIONS:

Natalizumab given every 4 weeks at a dosage of 3 to 5 mg/kg of body weight.

MAIN OUTCOME MEASURES:

Cranial magnetic resonance (MR) imaging before treatment and every 6 months thereafter.

RESULTS:

During 24, 16, and 15 months of treatment, no further relapses occurred in the 3 pediatric patients; all reported significant improvement in their quality of life. Follow-up MR imaging showed no new T2-weighted lesions or gadolinium-enhancing lesions. No adverse events were seen when dosage was adjusted to body weight.

CONCLUSIONS:

Natalizumab treatment was effective and well tolerated in our pediatric patients with RRMS who did not respond to initial immunomodulatory treatments. Therefore, it is a promising second-line therapy for pediatric patients with RRMS.

PMID:
19064754
DOI:
10.1001/archneur.65.12.1655
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center